NCT06680596Enrolling By Invitation2 期
A ctDNA Screening Program in Patients With HR+, HER2 Low Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor Followed by a Single Arm Phase II Trial of Trastuzumab-deruxtecan in Patients With Persistent ctDNA After 1 Month of Treatment With Endocrine Therapy Combined With CDK4/6 Inhibitor
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- Enrolling By Invitation
- 发起方
- UNICANCER
- 入组人数
- 80
- 试验地点
- 72
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
After an initial screening phase to identify patients with persistent blood circulating DNA tumors, patients will be enrolled in the treatment phase that was designed as an open-label, multicentre, phase II study, to test the efficacy of trastuzumab deruxtecan in terms of progression-free survival (PFS).
详细描述
Eligible patients to the screening phase are patients with hormone receptor positive (estrogen receptor and/or progesterone receptor >10%) and HER2 low or ultralow metastatic breast cancer who will receive standard first line therapy with CDK4-6i (any from the market), combined with aromatase inhibitor or fulvestrant. Patient persistence of tumor DNA in the blood at 4 weeks of this standard therapy will be included in the treatment phase with trastuzumab deruxtecan (T-DXd).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •SCREENING PHASE_________________________________________________________
- •Inclusion criteria
- •Patient must have signed the written informed consent for screening phase prior to any trial specific procedures.
- •Note: When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent.
- •Patient is ≥18 years of age.
- •Documented breast cancer that:
- •Is metastatic and eligible to biopsy for subsequent histological or cytological confirmation,
- •Is HER2 low (HER2 1+, or 2+ and in situ hybridization (ISH) negative) or HER2 ultra low (IHC 0 with incomplete and faint membrane staining in >0 and ≤10% of tumor cells) on the most recent tumor material available, as defined by the local pathologist under ASCO/CAP guidelines,
- •Is HR-positive (positive for estrogen receptor or progesterone receptor ≥10% of tumor cell nuclei are immunoreactive) in the metastatic setting.
- •Patient has either:
- •a metastatic relapse during or within 1 year after termination of the adjuvant endocrine therapy (AI resistant), or
- •a metastatic relapse more than one year of completing adjuvant AI or a de-novo metastatic breast cancer (AI sensitive/naive).
- •For AI resistant population: patient has previously gone through the ctDNA screening part of the SAFIR 03 - SCREENING/ARRIBA study and fulfilled all the inclusion criteria and none of the
排除标准
- •Patient did not receive any therapy in the metastatic setting.
- •Patient is eligible for a first-line treatment with a marketed CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) in combination with either AI or fulvestrant, according to its marketing authorisation.
- •Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status ≤
- •Patient has an adequate bone marrow and organ function.
- •Patient has a measurable or an evaluable disease according to Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST v1.1).
- •Availability of an archived metastatic tumor sample (FFPE) for exploratory research. Bone metastasis are accepted if tissue is representative of tumor tissue (at least 10% tumor cellularity).
- •Patient must be willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests and other study procedures.
- •Registration in a National Health Care System (or equivalent).
- •Exclusion criteria:
- •Patient is eligible to chemotherapy because of visceral crisis.
- •Patient has a breast cancer amenable for resection or radiation therapy with curative intent.
- •Prior exposure to antibody-drug conjugate or CDK4/6 inhibitors (in metastatic setting). CDK4/6 inhibitors given in adjuvant setting must be stopped for at least 12 months prior screening
- •Patient who has initiated the CDK4/6 inhibitor treatment.
- •Patient is unable to swallow tablets.
- •Patient has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis requiring steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at baseline
- •Patient has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product.
- •Patient has a history of severe hypersensitivity reactions to other monoclonal antibodies.
- •Person deprived of their liberty or under protective custody or guardianship.
- •Social, familial, or geographic factors that would interfere with study participation or follow-up.
- •TREATMENT PHASE_________________________________________________________
- •Inclusion criteria
- •Patient must have signed the written informed consent for the treatment phase prior to any trial specific procedures.
- •Note: When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent.
- •Patient must have discontinued CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) at least 7 days before enrolment, but no longer than 14 days
- •Patients must present a no drop of ctDNA determined by a ctDNA assay after 4 weeks of standard of care treatment with a CDK4/6 inhibitor
- •Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status ≤
- •Left ventricular ejection fraction (LVEF) ≥50% within 28 days prior to enrolment.
- •Participant has adequate bone marrow and organ function within 14 days before enrolment, defined as the following laboratory values:
- •Absolute neutrophil count (ANC) ≥1500/mm³,
- •platelet count ≥100,000/mm³,
- •haemoglobin ≥9.0 g/dl,
- •Serum creatinine ≤1.5 × upper limit of normal (ULN) or creatinine clearance ≥30 mL/min,
- •Serum albumin ≥2.5 g/dL,
- •Total bilirubin ≤1.5 × ULN (<3 ULN if Gilbert's disease),
- •In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN. If the participant has liver metastases, ALT and AST < 5 × ULN, he/she will be eligible for the study,
- •Adequate blood clotting function: defined as an international normalized ratio/prothrombin time ≤1.5 × ULN and either partial thromboplastin time or activated partial thromboplastin time within normal limits.
- •Note: Transfusion (red blood cell or platelet) or G-CSF administration is not allowed within 14 days prior to the day on which bone marrow function is assessed, or at any time after this day and prior to cycle 1 day
- •Women of childbearing potential must have a negative serum pregnancy test (with a sensitivity of at least 25 mIU/mL) result within 3 days of enrolment.
- •Men or women of childbearing potential must agree to the use of effective contraceptive for the study duration and for at least 7 months after the last dose of study treatment for women, and at least 4 months for men.
- •Patient must be willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests and other study procedures.
- •Exclusion criteria:
- •AI resistant patients who are eligible to SAFIR 03 - ARRIBA trial (i.e. PIK3CA mutated patients), until SAFIR 03 - ARRIBA study closure or study steering committee's decision.
- •Patient has received more than 2 cycles of the ongoing CDK4/6 inhibitor treatment combined with either AI or fulvestrant.
- •Patient has interrupted the ongoing CDK4/6 inhibitor treatment for more than 14 days.
- •Patient has evidence of clinical or radiological disease progression.
- •Patient has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline.
- •Note: Patients may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to >Grade 2 for at least 3 months prior to enrolment and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, such as: Chemotherapy-induced neuropathy and fatigue.
- •Patient has malignancies within 3 years, other than that under study, with the exception of: adequately resected non-melanoma skin cancer, curatively treated in-situ disease, other solid tumors curatively treated, or contralateral breast cancer.
- •Patient is at high medical risk because of severe or uncontrolled systemic disease, such as uncontrolled diabetes mellitus, clinically significant pulmonary disease, clinically significant neurological disorder, chronic pancreatitis, chronic active infection with hepatitis B virus, hepatitis C virus, or HIV, active untreated or uncontrolled fungal, bacterial or viral infections, active primary immunodeficiency etc.
- •Uncontrolled or significant cardiovascular disease, including any of the following:
- 另有 16 项未显示
研究组 & 干预措施
T-DXd
Experimental
T-DXd will be administrated as an intra-venous injection of 5.4 mg/kg every three weeks (1 cycle = 21-day treatment).
干预措施: trastuzumab derxutecan (Drug)
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: From first treatment administration to disease progression or death, up to 5 years
The progression-free survival is the length of time during and after treatment of the disease with T-DXd that a patient lives with the disease but it does not get worse.
次要结局
- Overall survival (OS)(From the first T-DXd administration to death due to any cause, up to 5 years)
- Objective response Rate (ORR)(From first T-DXd Administration to 6 months after the first administration of treatment, up to 5 years)
- Duration of response (DoR)(From the date of first documentation to disease progression or death, up to 5 years)
- Clinical benefit rate (CBR)(From first T-DXd Administration to 6 months after the first administration of treatment, up to 5 years)
- Time to response (TTR)(From the first T-DXd administration to objective response, up to 5 years)
- Toxicity during the study(Throughout study completion, up to 5 years)
研究者
研究点 (72)
Loading locations...
相似试验
进行中（未招募）
2 期
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or RibociclibBreast Cancer Stage IVNCT05625087UNICANCER162
招募中
1 期
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) metastatic breast cancer as a tool to select those who may benefit from the next course of fulvestrant in combination with alpelisib or ribociclib.Metastatic Breast Cancer HR+, HER2-MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104CTIS2022-502372-22-01nicancer1,080
招募中
2 期
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerER+ Breast CancerHER2-negative Breast CancerNCT04985266Royal Marsden NHS Foundation Trust1,100
暂停
2 期
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)Non-small Cell Lung Cancer Stage IINon-small Cell Lung Cancer Stage INon-small Cell Lung Cancer Stage IIINon-small Cell Lung CancerNCT04585477Stanford University80
招募中
不适用
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid TumorsHealthy VolunteerSolid Tumor CancerGenitourinary CancerGastrointestinal CancerSkin CancerHead and Neck CancerBreast CancerProstate CancerLung CancerMelanomaEsophageal CancerColon CancerSarcomaNCT04354064Washington University School of Medicine100